How Should Gynecological Sarcomas Be Managed?

  • Beatrice Seddon
  • Frederic Amant


Uterine sarcomas are malignant tumors of mesenchymal origin. They are rare, accounting for 8 % of all uterine tumors and 7 % of all soft tissue sarcomas. Uterine sarcomas are classified into uterine leiomyosarcomas, adenosarcomas, endometrial stromal sarcomas, and undifferentiated endometrial sarcomas. Uterine carcinosarcomas have historically been classified as uterine sarcomas but more recently have been recognized as a subtype of endometrial carcinoma, and so are not discussed here. For each uterine sarcoma subtype, we discuss epidemiology and diagnosis, histopathology, and management of early and advanced/metastatic disease with surgery, radiotherapy, and systemic therapy, discussing standard treatment and areas of controversy.


Soft Tissue Sarcoma National Comprehensive Cancer Network Figo Stage Gynecologic Oncology Group Uterine Sarcoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Brooks SE, Zhan M, Cote T, Baquet CR. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989–1999. Gynecol Oncol. 2004;93(1):204–8. Epub 2004/03/30.PubMedCrossRefGoogle Scholar
  2. 2.
    Toro JR, Travis LB, Wu HJ, Zhu K, Fletcher CD, Devesa SS. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: an analysis of 26,758 cases. Int J Cancer. 2006;119(12):2922–30. Epub 2006/10/03.PubMedCrossRefGoogle Scholar
  3. 3.
    Zaloudek C, Hendrickson M. Mesenchymal tumours of the uterus. In: Kumaran RJ, editor. Blaustein’s pathology of the female genital tract. New York: Springer; 2002. p. 561–615.Google Scholar
  4. 4.
    Abeler VM, Royne O, Thoresen S, Danielsen HE, Nesland JM, Kristensen GB. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology. 2009;54(3):355–64.PubMedCrossRefGoogle Scholar
  5. 5.
    McCluggage WG. Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas? J Clin Pathol. 2002;55(5):321–5. Epub 2002/05/03.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Amant F, Cadron I, Fuso L, Berteloot P, de Jonge E, Jacomen G, et al. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer. Gynecol Oncol. 2005;98(2):274–80. Epub 2005/06/24.PubMedCrossRefGoogle Scholar
  7. 7.
    Corrigendum to “FIGO staging for uterine sarcomas” [International Journal of Gynecology and Obstetrics. 2009;104:179]. Int J Gynecol Obstet. 2009;106(3):277.Google Scholar
  8. 8.
    FIGO Committee on Gynecologic Oncology. FIGO staging for uterine sarcomas. Int J Gynecol Obstet. 2009;104(3):179.Google Scholar
  9. 9.
    Dinh TA, Oliva EA, Fuller Jr AF, Lee H, Goodman A. The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990–1999) at the Massachusetts General Hospital. Gynecol Oncol. 2004;92(2):648–52.PubMedCrossRefGoogle Scholar
  10. 10.
    Cheng X, Yang G, Schmeler KM, Coleman RL, Tu X, Liu J, et al. Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapy. Gynecol Oncol. 2011;121(2):323–7. Epub 2011/02/01.PubMedCrossRefGoogle Scholar
  11. 11.
    Kapp DS, Shin JY, Chan JK. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer. 2008;112(4):820–30. Epub 2008/01/15.PubMedCrossRefGoogle Scholar
  12. 12.
    Sagae S, Yamashita K, Ishioka S, Nishioka Y, Terasawa K, Mori M, et al. Preoperative diagnosis and treatment results in 106 patients with uterine sarcoma in Hokkaido, Japan. Oncology. 2004;67(1):33–9. Epub 2004/10/02.PubMedCrossRefGoogle Scholar
  13. 13.
    Van den Bosch T, Coosemans A, Morina M, Timmerman D, Amant F. Screening for uterine tumours. Best Pract Res Clin Obstet Gynaecol. 2012;26(2):257–66. Epub 2011/11/15.PubMedCrossRefGoogle Scholar
  14. 14.
    Aviram R, Ochshorn Y, Markovitch O, Fishman A, Cohen I, Altaras MM, et al. Uterine sarcomas versus leiomyomas: gray-scale and Doppler sonographic findings. J Clin Ultrasound. 2005;33(1):10–3. Epub 2005/02/04.PubMedCrossRefGoogle Scholar
  15. 15.
    Hata K, Hata T, Maruyama R, Hirai M. Uterine sarcoma: can it be differentiated from uterine leiomyoma with Doppler ultrasonography? A preliminary report. Ultrasound Obstet Gynecol. 1997;9(2):101–4. Epub 1997/02/01.PubMedCrossRefGoogle Scholar
  16. 16.
    Szabo I, Szantho A, Csabay L, Csapo Z, Szirmai K, Papp Z. Color Doppler ultrasonography in the differentiation of uterine sarcomas from uterine leiomyomas. Eur J Gynaecol Oncol. 2002;23(1):29–34. Epub 2002/03/06.PubMedGoogle Scholar
  17. 17.
    McLucas B. Diagnosis, imaging and anatomical classification of uterine fibroids. Best Pract Res Clin Obstet Gynaecol. 2008;22(4):627–42. Epub 2008/03/11.PubMedCrossRefGoogle Scholar
  18. 18.
    Cornfeld D, Israel G, Martel M, Weinreb J, Schwartz P, McCarthy S. MRI appearance of mesenchymal tumors of the uterus. Eur J Radiol. 2010;74(1):241–9. Epub 2009/04/08.PubMedCrossRefGoogle Scholar
  19. 19.
    Kido A, Togashi K, Koyama T, Yamaoka T, Fujiwara T, Fujii S. Diffusely enlarged uterus: evaluation with MR imaging. Radiographics. 2003;23(6):1423–39. Epub 2003/11/15.PubMedCrossRefGoogle Scholar
  20. 20.
    Sahdev A, Sohaib SA, Jacobs I, Shepherd JH, Oram DH, Reznek RH. MR imaging of uterine sarcomas. AJR Am J Roentgenol. 2001;177(6):1307–11. Epub 2001/11/22.PubMedCrossRefGoogle Scholar
  21. 21.
    Tanaka YO, Nishida M, Tsunoda H, Okamoto Y, Yoshikawa H. Smooth muscle tumors of uncertain malignant potential and leiomyosarcomas of the uterus: MR findings. J Magn Reson Imaging. 2004;20(6):998–1007. Epub 2004/11/24.PubMedCrossRefGoogle Scholar
  22. 22.
    Nagamatsu A, Umesaki N, Li L, Tanaka T. Use of 18F-fluorodeoxyglucose positron emission tomography for diagnosis of uterine sarcomas. Oncol Rep. 2010;23(4):1069–76. Epub 2010/03/06.PubMedGoogle Scholar
  23. 23.
    Umesaki N, Tanaka T, Miyama M, Kawamura N, Ogita S, Kawabe J, et al. Positron emission tomography with (18)F-fluorodeoxyglucose of uterine sarcoma: a comparison with magnetic resonance imaging and power Doppler imaging. Gynecol Oncol. 2001;80(3):372–7. Epub 2001/03/27.PubMedCrossRefGoogle Scholar
  24. 24.
    Kitajima K, Murakami K, Kaji Y, Sugimura K. Spectrum of FDG PET/CT findings of uterine tumors. AJR Am J Roentgenol. 2010;195(3):737–43. Epub 2010/08/24.PubMedCrossRefGoogle Scholar
  25. 25.
    Shida M, Murakami M, Tsukada H, Ishiguro Y, Kikuchi K, Yamashita E, et al. F-18 fluorodeoxyglucose uptake in leiomyomatous uterus. Int J Gynecol Cancer. 2007;17(1):285–90. Epub 2007/02/13.PubMedCrossRefGoogle Scholar
  26. 26.
    Goto A, Takeuchi S, Sugimura K, Maruo T. Usefulness of Gd-DTPA contrast-enhanced dynamic MRI and serum determination of LDH and its isozymes in the differential diagnosis of leiomyosarcoma from degenerated leiomyoma of the uterus. Int J Gynecol Cancer. 2002;12(4):354–61. Epub 2002/07/30.PubMedCrossRefGoogle Scholar
  27. 27.
    Kawamura N, Ichimura T, Ito F, Shibata S, Takahashi K, Tsujimura A, et al. Transcervical needle biopsy for the differential diagnosis between uterine sarcoma and leiomyoma. Cancer. 2002;94(6):1713–20. Epub 2002/03/29.PubMedCrossRefGoogle Scholar
  28. 28.
    Bell SW, Kempson RL, Hendrickson MR. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol. 1994;18(6):535–58.PubMedCrossRefGoogle Scholar
  29. 29.
    Ioffe YJ, Li AJ, Walsh CS, Karlan BY, Leuchter R, Forscher C, et al. Hormone receptor expression in uterine sarcomas: prognostic and therapeutic roles. Gynecol Oncol. 2009;115(3):466–71. Epub 2009/09/22.PubMedCrossRefGoogle Scholar
  30. 30.
    Koivisto-Korander R, Butzow R, Koivisto AM, Leminen A. Immunohistochemical studies on uterine carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma: expression and prognostic importance of ten different markers. Tumour Biol. 2011;32(3):451–9. Epub 2010/12/17.PubMedCrossRefGoogle Scholar
  31. 31.
    Sutton GP, Stehman FB, Michael H, Young PC, Ehrlich CE. Estrogen and progesterone receptors in uterine sarcomas. Obstet Gynecol. 1986;68(5):709–14. Epub 1986/11/01.PubMedGoogle Scholar
  32. 32.
    Bodner K, Bodner-Adler B, Kimberger O, Czerwenka K, Leodolter S, Mayerhofer K. Estrogen and progesterone receptor expression in patients with uterine leiomyosarcoma and correlation with different clinicopathological parameters. Anticancer Res. 2003;23(1B):729–32. Epub 2003/04/12.PubMedGoogle Scholar
  33. 33.
    O’Cearbhaill R, Zhou Q, Iasonos A, Soslow RA, Leitao MM, Aghajanian C, et al. Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors. Gynecol Oncol. 2010;116(3):424–9. Epub 2009/11/26.PubMedCrossRefGoogle Scholar
  34. 34.
    Leitao Jr MM, Hensley ML, Barakat RR, Aghajanian C, Gardner GJ, Jewell EL, et al. Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcoma. Gynecol Oncol. 2012;124(3):558–62. Epub 2011/11/17.PubMedCrossRefGoogle Scholar
  35. 35.
    Reich O, Regauer S, Urdl W, Lahousen M, Winter R. Expression of oestrogen and progesterone receptors in low-grade endometrial stromal sarcomas. Br J Cancer. 2000;82(5):1030–4. Epub 2000/03/29.PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    Chu MC, Mor G, Lim C, Zheng W, Parkash V, Schwartz PE. Low-grade endometrial stromal sarcoma: hormonal aspects. Gynecol Oncol. 2003;90(1):170–6. Epub 2003/06/25.PubMedCrossRefGoogle Scholar
  37. 37.
    Balleine RL, Earls PJ, Webster LR, Mote PA, deFazio A, Harnett PR, et al. Expression of progesterone receptor A and B isoforms in low-grade endometrial stromal sarcoma. Int J Gynecol Pathol. 2004;23(2):138–44. Epub 2004/04/16.PubMedCrossRefGoogle Scholar
  38. 38.
    Zhu XQ, Shi YF, Cheng XD, Zhao CL, Wu YZ. Immunohistochemical markers in differential diagnosis of endometrial stromal sarcoma and cellular leiomyoma. Gynecol Oncol. 2004;92(1):71–9. Epub 2004/01/31.PubMedCrossRefGoogle Scholar
  39. 39.
    Kurihara S, Oda Y, Ohishi Y, Iwasa A, Takahira T, Kaneki E, et al. Endometrial stromal sarcomas and related high-grade sarcomas: immunohistochemical and molecular genetic study of 31 cases. Am J Surg Pathol. 2008;32(8):1228–38. Epub 2008/06/27.PubMedCrossRefGoogle Scholar
  40. 40.
    Veras E, Zivanovic O, Jacks L, Chiappetta D, Hensley M, Soslow R. “Low-grade leiomyosarcoma” and late-recurring smooth muscle tumors of the uterus: a heterogenous collection of frequently misdiagnosed tumors associated with an overall favorable prognosis relative to conventional uterine leiomyosarcomas. Am J Surg Pathol. 2011;35(11):1626–37. Epub 2011/09/17.PubMedCrossRefGoogle Scholar
  41. 41.
    Amant F, Moerman P, Vergote I. Report of an unusual problematic uterine smooth muscle neoplasm, emphasizing the prognostic importance of coagulative tumor cell necrosis. Int J Gynecol Cancer. 2005;15(6):1210–2. Epub 2005/12/14.PubMedCrossRefGoogle Scholar
  42. 42.
    Giuntoli 2nd RL, Metzinger DS, DiMarco CS, Cha SS, Sloan JA, Keeney GL, et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol. 2003;89(3):460–9. Epub 2003/06/12.PubMedCrossRefGoogle Scholar
  43. 43.
    Leitao MM, Sonoda Y, Brennan MF, Barakat RR, Chi DS. Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus. Gynecol Oncol. 2003;91(1):209–12. Epub 2003/10/08.PubMedCrossRefGoogle Scholar
  44. 44.
    Major FJ, Blessing JA, Silverberg SG, Morrow CP, Creasman WT, Currie JL, et al. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group Study. Cancer. 1993;71(4 Suppl):1702–9. Epub 1993/02/15.PubMedCrossRefGoogle Scholar
  45. 45.
    Amant F, Coosemans A, Debiec-Rychter M, Timmerman D, Vergote I. Clinical management of uterine sarcomas. Lancet Oncol. 2009;10(12):1188–98. Epub 2009/12/05.PubMedCrossRefGoogle Scholar
  46. 46.
    Park JY, Park SK, Kim DY, Kim JH, Kim YM, Kim YT, et al. The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma. Gynecol Oncol. 2011;122(2):255–9. Epub 2011/05/14.PubMedCrossRefGoogle Scholar
  47. 47.
    Milman D, Zalel Y, Biran H, Open M, Caspi B, Hagay Z, et al. Unsuspected uterine leiomyosarcoma discovered during treatment with a gonadotropin-releasing hormone analogue: a case report and literature review. Eur J Obstet Gynecol Reprod Biol. 1998;76(2):237–40. Epub 1998/03/03.PubMedCrossRefGoogle Scholar
  48. 48.
    Sampath S, Schultheiss TE, Ryu JK, Wong JY. The role of adjuvant radiation in uterine sarcomas. Int J Radiat Oncol Biol Phys. 2010;76(3):728–34. Epub 2009/08/25.PubMedCrossRefGoogle Scholar
  49. 49.
    Reed NS, Mangioni C, Malmstrom H, Scarfone G, Poveda A, Pecorelli S, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer. 2008;44(6):808–18. Epub 2008/04/02.PubMedCrossRefGoogle Scholar
  50. 50.
    Sampath S, Gaffney DK. Role of radiotherapy treatment of uterine sarcoma. Best Pract Res Clin Obstet Gynaecol. 2011;25(6):761–72. Epub 2011/07/26.PubMedCrossRefGoogle Scholar
  51. 51.
    Omura GA, Blessing JA, Major F, Lifshitz S, Ehrlich CE, Mangan C, et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study. J Clin Oncol. 1985;3(9):1240–5. Epub 1985/09/01.PubMedGoogle Scholar
  52. 52.
    Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet. 1997;350(9092):1647–54. Epub 1997/12/24.CrossRefGoogle Scholar
  53. 53.
    Woll P, van Glabbeke M, Hohenberger P, Le Cesne A, Gronchi A, Hoekstra HJ, Radford JA, van Coevorden F, Blay J, editors. Adjuvant chemotherapy (CT) with doxorubicin and ifosfamide in resected soft tissue sarcoma (STS): interim analysis of a randomised phase III trial. Chicago: American Society of Clinical Oncology; 2007.Google Scholar
  54. 54.
    Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002;20(12):2824–31. Epub 2002/06/18.PubMedCrossRefGoogle Scholar
  55. 55.
    Hensley ML, Blessing JA, Degeest K, Abulafia O, Rose PG, Homesley HD. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol. 2008;109(3):323–8. Epub 2008/04/09.PubMedCentralPubMedCrossRefGoogle Scholar
  56. 56.
    Hensley ML, Blessing JA, Mannel R, Rose PG. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 2008;109(3):329–34. Epub 2008/06/07.PubMedCentralPubMedCrossRefGoogle Scholar
  57. 57.
    Hensley ML, Ishill N, Soslow R, Larkin J, Abu-Rustum N, Sabbatini P, et al. Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: results of a prospective study. Gynecol Oncol. 2009;112(3):563–7. Epub 2009/01/13.PubMedCrossRefGoogle Scholar
  58. 58.
    Giuntoli 2nd RL, Garrett-Mayer E, Bristow RE, Gostout BS. Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma. Gynecol Oncol. 2007;106(1):82–8. Epub 2007/04/17.PubMedCrossRefGoogle Scholar
  59. 59.
    Smith R, Pak Y, Kraybill W, Kane 3rd JM. Factors associated with actual long-term survival following soft tissue sarcoma pulmonary metastasectomy. Eur J Surg Oncol. 2009;35(4):356–61. Epub 2008/02/26.PubMedCrossRefGoogle Scholar
  60. 60.
    Clavero JM, Deschamps C, Cassivi SD, Allen MS, Nichols 3rd FC, Barrette BA, et al. Gynecologic cancers: factors affecting survival after pulmonary metastasectomy. Ann Thorac Surg. 2006;81(6):2004–7. Epub 2006/05/30.PubMedCrossRefGoogle Scholar
  61. 61.
    Sleijfer S, Seynaeve C, Verweij J. Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care. Oncologist. 2005;10(10):833–41. Epub 2005/11/30.PubMedCrossRefGoogle Scholar
  62. 62.
    Spira AI, Ettinger DS. The use of chemotherapy in soft-tissue sarcomas. Oncologist. 2002;7(4):348–59. Epub 2002/08/20.PubMedCrossRefGoogle Scholar
  63. 63.
    Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009;27(25):4188–96. Epub 2009/08/05.PubMedCrossRefGoogle Scholar
  64. 64.
    Samuels BL, Chawla S, Patel S, von Mehren M, Hamm J, Kaiser PE, et al. Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study. Ann Oncol. 2013;24(6):1703–9. Epub 2013/02/07.PubMedCrossRefGoogle Scholar
  65. 65.
    Sanfilippo R, Grosso F, Jones RL, Banerjee S, Pilotti S, D’Incalci M, et al. Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers. Gynecol Oncol. 2011;123(3):553–6. Epub 2011/09/16.PubMedCrossRefGoogle Scholar
  66. 66.
    Chawla SP, Blay J, Ray-Coquard I, Le Cesne A, Staddon AP, Milhem MM, Penel N, et al., editors. Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridafirololimus as maintenance therapy in advanced sarcoma patients following clinical benefit from prior standard cytotoxic chemotherapy. Chicago: American Society of Clinical Oncology; 2011. Journal of Clinical Oncology.Google Scholar
  67. 67.
    van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879–86. Epub 2012/05/19.PubMedCrossRefGoogle Scholar
  68. 68.
    Koivisto-Korander R, Leminen A, Heikinheimo O. Mifepristone as treatment of recurrent progesterone receptor-positive uterine leiomyosarcoma. Obstet Gynecol. 2007;109(2 Pt2):512–4. Epub 2007/02/03.PubMedCrossRefGoogle Scholar
  69. 69.
    Lo CA, Huang SC, Ho CL, Tzeng CC, Chou CY, Hsu KF. Discordant responses to progestin in a patient with uterine low-grade smooth-muscle tumors metastatic to the lung. J Obstet Gynaecol Res. 2005;31(5):394–8. Epub 2005/09/24.PubMedCrossRefGoogle Scholar
  70. 70.
    Uchida T, Nakakawaji K, Sakamoto J, Kojima H, Murakami H, Kato J, et al. The effectiveness of medroxyprogesterone in the treatment of multiple metastasizing leiomyosarcomas: report of a case. Surg Today. 1996;26(2):138–41. Epub 1996/01/01.PubMedCrossRefGoogle Scholar
  71. 71.
    Hardman MP, Roman JJ, Burnett AF, Santin AD. Metastatic uterine leiomyosarcoma regression using an aromatase inhibitor. Obstet Gynecol. 2007;110(2 Pt 2):518–20. Epub 2007/08/02.PubMedCrossRefGoogle Scholar
  72. 72.
    George S, Manola JB, Butrynski JE, Morgan JA, Nucci MR, Ramaiya N, Quek RH, et al. Targeting hormone receptors in uterine leiomyosarcoma: phase II clinical study of letrozole in women with advanced uterine leiomyosarcoma expressing estrogen and/or progesterone receptors. Prague: Connective Tissue Oncology Society; 2012. p. 102–3.Google Scholar
  73. 73.
    Evans HL. Endometrial stromal sarcoma and poorly differentiated endometrial sarcoma. Cancer. 1982;50(10):2170–82. Epub 1982/11/15.PubMedCrossRefGoogle Scholar
  74. 74.
    Piver MS, Rutledge FN, Copeland L, Webster K, Blumenson L, Suh O. Uterine endolymphatic stromal myosis: a collaborative study. Obstet Gynecol. 1984;64(2):173–8. Epub 1984/08/01.PubMedGoogle Scholar
  75. 75.
    Chan JK, Kawar NM, Shin JY, Osann K, Chen LM, Powell CB, et al. Endometrial stromal sarcoma: a population-based analysis. Br J Cancer. 2008;99(8):1210–5. Epub 2008/09/25.PubMedCentralPubMedCrossRefGoogle Scholar
  76. 76.
    Schick U, Bolukbasi Y, Thariat J, Abdah-Bortnyak R, Kuten A, Igdem S, et al. Outcome and prognostic factors in endometrial stromal tumors: a Rare Cancer Network study. Int J Radiat Oncol Biol Phys. 2012;82(5):e757–63. Epub 2012/02/04.PubMedCrossRefGoogle Scholar
  77. 77.
    Chang KL, Crabtree GS, Lim-Tan SK, Kempson RL, Hendrickson MR. Primary uterine endometrial stromal neoplasms. A clinicopathologic study of 117 cases. Am J Surg Pathol. 1990;14(5):415–38.PubMedCrossRefGoogle Scholar
  78. 78.
    Norris HJ, Taylor HB. Mesenchymal tumors of the uterus. I. A clinical and pathological study of 53 endometrial stromal tumors. Cancer. 1966;19(6):755–66.PubMedCrossRefGoogle Scholar
  79. 79.
    Oliva E, Clement PB, Young RH. Endometrial stromal tumors: an update on a group of tumors with a protean phenotype. Adv Anat Pathol. 2000;7(5):257–81. Epub 2000/09/08.PubMedCrossRefGoogle Scholar
  80. 80.
    Koontz JI, Soreng AL, Nucci M, Kuo FC, Pauwels P, van Den Berghe H, et al. Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors. Proc Natl Acad Sci U S A. 2001;98(11):6348–53. Epub 2001/05/24.PubMedCentralPubMedCrossRefGoogle Scholar
  81. 81.
    Nucci MR, Harburger D, Koontz J, Dal Cin P, Sklar J. Molecular analysis of the JAZF1-JJAZ1 gene fusion by RT-PCR and fluorescence in situ hybridization in endometrial stromal neoplasms. Am J Surg Pathol. 2007;31(1):65–70. Epub 2007/01/02.PubMedCrossRefGoogle Scholar
  82. 82.
    Micci F, Panagopoulos I, Bjerkehagen B, Heim S. Consistent rearrangement of chromosomal band 6p21 with generation of fusion genes JAZF1/PHF1 and EPC1/PHF1 in endometrial stromal sarcoma. Cancer Res. 2006;66(1):107–12. Epub 2006/01/07.PubMedCrossRefGoogle Scholar
  83. 83.
    Della Badia C, Karini H. Endometrial stromal sarcoma diagnosed after uterine morcellation in laparoscopic supracervical hysterectomy. J Minim Invasive Gynecol. 2010;17(6):791–3. Epub 2010/10/20.PubMedCrossRefGoogle Scholar
  84. 84.
    Park JY, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH. The impact of tumor morcellation during surgery on the outcomes of patients with apparently early low-grade endometrial stromal sarcoma of the uterus. Ann Surg Oncol. 2011;18(12):3453–61. Epub 2011/05/05.PubMedCrossRefGoogle Scholar
  85. 85.
    Shah JP, Bryant CS, Kumar S, Ali-Fehmi R, Malone Jr JM, Morris RT. Lymphadenectomy and ovarian preservation in low-grade endometrial stromal sarcoma. Obstet Gynecol. 2008;112(5):1102–8. Epub 2008/11/04.PubMedCrossRefGoogle Scholar
  86. 86.
    Amant F, De Knijf A, Van Calster B, Leunen K, Neven P, Berteloot P, et al. Clinical study investigating the role of lymphadenectomy, surgical castration and adjuvant hormonal treatment in endometrial stromal sarcoma. Br J Cancer. 2007;97(9):1194–9. Epub 2007/09/27.PubMedCentralPubMedCrossRefGoogle Scholar
  87. 87.
    Barney B, Tward JD, Skidmore T, Gaffney DK. Does radiotherapy or lymphadenectomy improve survival in endometrial stromal sarcoma? Int J Gynecol Cancer. 2009;19(7):1232–8. Epub 2009/10/14.PubMedCrossRefGoogle Scholar
  88. 88.
    Dos Santos LA, Garg K, Diaz JP, Soslow RA, Hensley ML, Alektiar KM, et al. Incidence of lymph node and adnexal metastasis in endometrial stromal sarcoma. Gynecol Oncol. 2011;121(2):319–22. Epub 2011/02/01.PubMedCrossRefGoogle Scholar
  89. 89.
    Gadducci A, Sartori E, Landoni F, Zola P, Maggino T, Urgesi A, et al. Endometrial stromal sarcoma: analysis of treatment failures and survival. Gynecol Oncol. 1996;63(2):247–53. Epub 1996/11/01.PubMedCrossRefGoogle Scholar
  90. 90.
    Li AJ, Giuntoli 2nd RL, Drake R, Byun SY, Rojas F, Barbuto D, et al. Ovarian preservation in stage I low-grade endometrial stromal sarcomas. Obstet Gynecol. 2005;106(6):1304–8. Epub 2005/12/02.PubMedCrossRefGoogle Scholar
  91. 91.
    Kim WY, Lee JW, Choi CH, Kang H, Kim TJ, Kim BG, et al. Low-grade endometrial stromal sarcoma: a single center’s experience with 22 cases. Int J Gynecol Cancer. 2008;18(5):1084–9. Epub 2008/01/09.PubMedCrossRefGoogle Scholar
  92. 92.
    Leath 3rd CA, Huh WK, Hyde Jr J, Cohn DE, Resnick KE, Taylor NP, et al. A multi-institutional review of outcomes of endometrial stromal sarcoma. Gynecol Oncol. 2007;105(3):630–4. Epub 2007/02/27.PubMedCrossRefGoogle Scholar
  93. 93.
    Thomas MB, Keeney GL, Podratz KC, Dowdy SC. Endometrial stromal sarcoma: treatment and patterns of recurrence. Int J Gynecol Cancer. 2009;19(2):253–6. Epub 2009/04/28.PubMedCrossRefGoogle Scholar
  94. 94.
    Delaney CL, Saleem H, Karapetis C, Spark JI. Curative resection and reconstruction of the inferior vena cava after extensive infiltration with low-grade endometrial stromal sarcoma. Phlebology. 2013;28(1):51–3. Epub 2012/03/01.PubMedGoogle Scholar
  95. 95.
    Renzulli P, Weimann R, Barras JP, Carrel TP, Candinas D. Low-grade endometrial stromal sarcoma with inferior vena cava tumor thrombus and intracardiac extension: radical resection may improve recurrence free survival. Surg Oncol. 2009;18(1):57–64. Epub 2008/08/19.PubMedCrossRefGoogle Scholar
  96. 96.
    Yokoyama Y, Ono Y, Sakamoto T, Fukuda I, Mizunuma H. Asymptomatic intracardiac metastasis from a low-grade endometrial stromal sarcoma with successful surgical resection. Gynecol Oncol. 2004;92(3):999–1001. Epub 2004/02/27.PubMedCrossRefGoogle Scholar
  97. 97.
    Tzakas E, Liu S, Todd RW, Redman CW. Hormonal therapy with letrozole prior to surgical management of recurrent metastatic low-grade endometrial stromal sarcoma (LGESS). J Obstet Gynaecol. 2009;29(8):778–9. Epub 2009/10/14.PubMedCrossRefGoogle Scholar
  98. 98.
    Katz L, Merino MJ, Sakamoto H, Schwartz PE. Endometrial stromal sarcoma: a clinicopathologic study of 11 cases with determination of estrogen and progestin receptor levels in three tumors. Gynecol Oncol. 1987;26(1):87–97. Epub 1987/01/01.PubMedCrossRefGoogle Scholar
  99. 99.
    Scribner Jr DR, Walker JL. Low-grade endometrial stromal sarcoma preoperative treatment with Depo-Lupron and Megace. Gynecol Oncol. 1998;71(3):458–60. Epub 1999/01/15.PubMedCrossRefGoogle Scholar
  100. 100.
    Burke C, Hickey K. Treatment of endometrial stromal sarcoma with a gonadotropin-releasing hormone analogue. Obstet Gynecol. 2004;104(5 Pt 2):1182–4. Epub 2004/11/02.PubMedCrossRefGoogle Scholar
  101. 101.
    Maluf FC, Sabbatini P, Schwartz L, Xia J, Aghajanian C. Endometrial stromal sarcoma: objective response to letrozole. Gynecol Oncol. 2001;82(2):384–8. Epub 2001/09/05.PubMedCrossRefGoogle Scholar
  102. 102.
    Spano JP, Soria JC, Kambouchner M, Piperno-Neuman S, Morin F, Morere JF, et al. Long-term survival of patients given hormonal therapy for metastatic endometrial stromal sarcoma. Med Oncol. 2003;20(1):87–93. Epub 2003/04/01.PubMedCrossRefGoogle Scholar
  103. 103.
    Omura GA, Major FJ, Blessing JA, Sedlacek TV, Thigpen JT, Creasman WT, et al. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer. 1983;52(4):626–32. Epub 1983/08/15.PubMedCrossRefGoogle Scholar
  104. 104.
    Amant F, Vergote I, Moerman P. The classification of a uterine sarcoma as ‘high-grade endometrial stromal sarcoma’ should be abandoned. Gynecol Oncol. 2004;95(2):412–3; author reply 3. Epub 2004/10/20.PubMedCrossRefGoogle Scholar
  105. 105.
    Chiang S, Oliva E. Cytogenetic and molecular aberrations in endometrial stromal tumors. Human Pathol. 2011;42(5):609–17. Epub 2011/03/23.CrossRefGoogle Scholar
  106. 106.
    Caudell JJ, Deavers MT, Slomovitz BM, Lu KH, Broaddus RR, Gershenson DM, et al. Imatinib mesylate (gleevec) – targeted kinases are expressed in uterine sarcomas. Appl Immunohistochem Mol Morphol. 2005;13(2):167–70. Epub 2005/05/17.PubMedCrossRefGoogle Scholar
  107. 107.
    Moinfar F, Regitnig P, Tabrizi AD, Denk H, Tavassoli FA. Expression of androgen receptors in benign and malignant endometrial stromal neoplasms. Virchows Arch. 2004;444(5):410–4. Epub 2004/03/10.PubMedCrossRefGoogle Scholar
  108. 108.
    Coosemans A, Nik SA, Caluwaerts S, Lambin S, Verbist G, Van Bree R, et al. Upregulation of Wilms’ tumour gene 1 (WT1) in uterine sarcomas. Eur J Cancer. 2007;43(10):1630–7. Epub 2007/05/29.PubMedCrossRefGoogle Scholar
  109. 109.
    Coosemans A, Van Calster B, Verbist G, Moerman P, Vergote I, Van Gool SW, et al. Wilms tumor gene 1 (WT1) is a prognostic marker in high-grade uterine sarcoma. Int J Gynecol Cancer. 2011;21(2):302–8. Epub 2011/07/08.PubMedGoogle Scholar
  110. 110.
    Amant F, Vloeberghs V, Woestenborghs H, Debiec-Rychter M, Verbist L, Moerman P, et al. ERBB-2 gene overexpression and amplification in uterine sarcomas. Gynecol Oncol. 2004;95(3):583–7. Epub 2004/12/08.PubMedCrossRefGoogle Scholar
  111. 111.
    Abeler VM, Nenodovic M. Diagnostic immunohistochemistry in uterine sarcomas: a study of 397 cases. Int J Gynecol Pathol. 2011;30(3):236–43. Epub 2011/04/06.PubMedCrossRefGoogle Scholar
  112. 112.
    Gadducci A, Cosio S, Romanini A, Genazzani AR. The management of patients with uterine sarcoma: a debated clinical challenge. Crit Rev Oncol Hematol. 2008;65(2):129–42. Epub 2007/08/21.PubMedCrossRefGoogle Scholar
  113. 113.
    Network NCC. NCCN clinical practice guidelines in oncology: uterine neoplasms version 3.2012. 2012 [cited 2012 04.06.12; Practice guidelines]. Available from:
  114. 114.
    Haberal A, Kayikcioglu F, Boran N, Caliskan E, Ozgul N, Kose MF. Endometrial stromal sarcoma of the uterus: analysis of 25 patients. Eur J Obstet Gynecol Reprod Biol. 2003;109(2):209–13. Epub 2003/07/16.PubMedCrossRefGoogle Scholar
  115. 115.
    Li N, Wu LY, Zhang HT, An JS, Li XG, Ma SK. Treatment options in stage I endometrial stromal sarcoma: a retrospective analysis of 53 cases. Gynecol Oncol. 2008;108(2):306–11. Epub 2007/12/07.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  1. 1.Department of OncologyUniversity College HospitalLondonUK
  2. 2.Department of Gynaecological OncologyUniversity HospitalsLeuvenBelgium

Personalised recommendations